Sensei reports solnerstotug 14% ORR in PD-(L)1 resistant tumors; Phase 2 planned Q1 2026

Sensei Biotherapeutics, Inc.

14% ORR (3/21 evaluable) and 62% DCR in PD-(L)1 resistant 'hot' tumors; nearly 3x historical rechallenge response.
One durable CR in Merkel Cell Carcinoma (42+ weeks) and two PRs (MCC and MSI-H CRC, 12+ and 36+ weeks).
All patients with tumor shrinkage remain on study, suggesting potential for deepening responses.
Solnerstotug well tolerated: no DLTs; mild CRS in 4/60 patients (Grade 1 only).
Phase 2 initiation expected Q1 2026, subject to sufficient capital.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.